Professional Documents
Culture Documents
Goldman
GoldmanSachs
SachsIndia
IndiaEvents
EventsCalendar
Calendar
Capital
Autos Cements
Goods APRIL
Infra- MAY
Healthcare IT Services
structure
Material Events
Results
(non results)
Source: Company data, Goldman Sachs Research estimates.
sandeep.pandya@gs.com
24-Apr-10 4QFY10 results MRTI.BO Maruti Suzuki India
28-Apr-10 4QFY10 results Not Covered by GS MAHM.BO Mahindra & Mahindra
28-Apr-10 4QFY10 (Standalone) TAMO.BO Tata Motors
Sandeep Pandya
Capital Goods Expected Date Event Material Implication / Market Impact Ticker Company
16-Apr-2010 FY2010 results CCRI.BO Container Corporation of India
30-Apr-2010 FY2010 results GATE.BO Gateway Distriparks
April 2010 We expect commissioning of L&T This would be the first instance of a private player LART.BO Larsen & Toubro
- MHI Turbine generators' Surat commissioning power equipment manufacturing capacity in
facility India and would add 4,000 MW to India's power equipment
manufacturing capacity which is currently dominated by
11-May-2010 FY2010 results BHEL"s 15,000 MW capacity SNTX.BO Sintex Industries
15-May-2010 FY2010 results EKCL.BO Everest Kanto Cylinder
18-May-2010 FY2010 results PUJL.BO Punj Lloyd
27-May-2010 FY2010 results We expect strong revenue performance ( historically Q4 is theBHEL.BO Bharat Heavy Electricals
ishan.sethi@gs.com
Cements Expected Date Event Material Implication / Market Impact Ticker Company
10-Apr-2010 Pan-India cement dispatch data We expect cement dispatch data to be strong till onset of Cement sector
monsoon in July - FY11E cement consumption forecast at 11%
21-Apr-2010 FY2010 results yoy ULTC.BO Ultratech Cement
22-Apr-2010 1QFY2010 results ACC.BO ACC
22-Apr-2010 1QFY2010 results ABUJ.BO Ambuja Cements
10-May-2010 Pan-India cement dispatch data Cement sector
19-May-2010 FY2010 results GRAS.BO Grasim Industries
10-Jun-2010 Pan-India cement dispatch data Cement sector
pritesh.vinay@gs.com
1QFY2011 Listing of Samruddhi Cement Timely listing of Samruddhi Cement would ensure that the GRAS.BO, Grasim/Ultratech
91(22)6616-9038
(Grasim's cement subsidiary) entire consolidation process would be completed by 2QFY2011; ULTC.BO
implying potential rerating for Ultratech Cements. Post
consolidation, Ultratech Cements would emerge as India’s
largest cement company with a total capacity of 49 mtpa
representing 20% of all-India capacity.
Goldman Sachs India - Key events to watch for during April - June 2010
Consumer Expected Date Event Material Implication / Market Impact Ticker Company
vishnu.gopal@gs.com
29-Apr-2010 4QFY10 results DABU.BO Dabur India
21-May-2010 4QFY10 results To look for updates on price increases to cover increased ITC.BO ITC
excise duty
Vishnu Gopal
91(22)6616-9046
23-May-2010 1QFY10 results NEST.BO Nestle India
25-May-2010 4QFY10 results To look for impact of price reductions on margins and also HLL.BO Hindustan Unilever
whether pricing strategy has led to increase in volumes/market
28-May-2010 4QFY10 results shares
To look for increases in effective tax rate as deduction allowed COLG.BO Colgate Palmolive (India)
on production from Baddi set to expire.
Economics Expected Date Event Material Implication / Market Impact Ticker Company
12-Apr-2010 February IP We expect the strength in industrial activity to continue
14-Apr-2010 March WPI inflation We expect WPI inflation to be higher than 10% in the March
reading
20-Apr-2010 RBI Monetary policy meeting We expect the RBI to hike the reverse repo and repo rates by
25 bp each at its next policy meeting. We expect a cumulative
increase in effective policy rates of 300 bp in 2010, in part by
hiking the repo and reverse repo rates and in part by moving
the effective rate from the floor of the corridor (reverse repo) to
the ceiling (repo).
tushar.poddar@gs.com
21-May-2010 GDP release We expect 4Q FY10 GDP to be above 8%, in line with very
strong readings on IP, PMI and other co-incident indicators.
12-Jun-2010 April IP We expect the strength in industrial activity to continue
14-Jun-2010 May WPI inflation We expect headline WPI inflation to remain high, although food
prices begin to moderate
Financials Expected Date Event Material Implication / Market Impact Ticker Company
1-Apr-2010 4QFY10 results AXBK.BO Axis Bank
20-Apr-2010 RBI Monetary Policy Credit growth guidance for FY2010-FY2011. We expect RBI to Financials
begin its policy tightening cycle through rate hikes Sector
22-Apr-2010 4QFY10 results YESB.BO Yes Bank
23-Apr-2010 4QFY10 results HDBK.BO HDFC Bank
23-Apr-2010 4QFY10 results LICH.BO LIC Housing Finance
25-Apr-2010 4QFY10 results ICBK.BO ICICI Bank
27-Apr-2010 4QFY10 results BOB.BO Bank of Baroda
28-Apr-2010 4QFY10 results IDFC.BO Infrastructure Development Finance
tabassum.inamdar@gs.com
Healthcare Expected Date Event Material Implication / Market Impact Ticker Company
24-Apr-2010 4QFY10 results CIPL.BO Cipla
24-Apr-2010 4QFY10 results PIRA.BO Piramal Healthcare
24-Apr-2010 1QFY10 results RANB.BO Ranbaxy Laboratories
28-Apr-2010 4QFY10 results BION.BO Biocon
28-Apr-2010 4QFY10 results CADI.BO Cadila Healthcare
30-Jun-2010 4QFY10 results APLH.BO Apollo Hospitals
30-Jun-2010 4QFY10 results REDY.BO Dr. Reddy's Laboratories
30-Jun-2010 4QFY10 results FOHE.BO Fortis Healthcare
30-Jun-2010 4QFY10 results GLEN.BO Glenmark Pharmaceuticals
30-Jun-2010 4QFY10 results LUPN.BO Lupin
30-Jun-2010 4QFY10 results SUN.BO Sun Pharmaceutical Industries
1Q FY11 Fondaparinux ANDA approval This is one of 2-3 most imp products for DRL for 2010. Approval REDY.BO Dr. Reddy's Laboratories
here could have a positive impact on the stock
1Q FY11 Summary judgment from NY If the verdict is favorable for Sun, could eliminate some of the SUN.BO Sun Pharmaceutical Industries
Court on litigation with Taro Taro overhang on the stock.
2Q FY10 FDA reinspection of Dewas plant Positive results could remove the overhang on the company RANB.BO Ranbaxy Laboratories
and its results
balaji.prasad@gs.com
1Q FY11 IPO of Glenmark Generics Ltd - Clarity on future generics business for Glenmark GLEN.BO Glenmark Pharmaceuticals
its generic business
Balaji Prasad
1Q FY11 Court hearing on Tarka The 30-month stay on Tarka ends in May and should come up GLEN.BO Glenmark Pharmaceuticals
91(22)6616-9179
IT Services Expected Date Event Material Implication / Market Impact Ticker Company
balaji.prasad@gs.com
13-Apr-2010 4QFY10 results Guidance for FY11 and outlook on IT spending budgets and INFY.BO Infosys Technologies
19-Apr-2010 4QFY10 results hiring TCS.BO Tata Consultancy Services Ltd.
Balaji Prasad
Infrastructure Expected Date Event Material Implication / Market Impact Ticker Company
27-Apr-2010 FY2010 results Expect strong volume growth in the cement segment and JAIA.BO Jaiprakash Associates
strong pick-up in realizations from real estate sales
29-Apr-2010 FY2010 results GVKP.BO GVK Power and Infrastructure
Apr-10 Salem - Kumarapalyam and As operations stabilize we expect daily collections of Rs1.5-1.7 IVRC.BO IVRCL Infrastructure
Jalandhar - Amritsar projects to mn on each of these two BOT projects.
start tolling
21-May-2010 FY2010 results We expect high yoy sales and EPS growth, driven by traction in IRBI.BO IRB Infrastructure Developers
the construction business.
ishan.sethi@gs.com
29-May-2010 FY2010 results We expect strong performance with execution in other states IVRC.BO IVRCL Infrastructure and Projects
91(22)6616-9048
Media Expected Date Event Material Implication / Market Impact Ticker Company
22-Apr-2010 FY2010 results We expect a strong performance in advertising revenues this ZEE.BO Zee Entertainment Enterprises
ishan.sethi@gs.com
quarter - reflecting the ad-rate hikes that the company
undertook earlier in 2010. Revenues from the 6 regional GECs
91(22)6616-9048
Ishan Sethi would also be consolidated into reported results.
30-May-2010 FY2010 results DSTV.BO Dish TV India
30-May-2010 FY2010 results Company has witnessed exceptionally strong growth over the SUTV.BO Sun TV Network
past two quarters. Any change in momentum would be
relevant.
Metals and MiningExpected Date Event Material Implication / Market Impact Ticker Company
20-Apr-2010 FY2010 results SESA.BO Sesa Goa
22-Apr-2010 FY2010 results HZNC.BO Hindustan Zinc
28-Apr-2010 FY2010 results STRL.BO Sterlite Industries (India)
April-10 Arbitration hearing on the terms A slow progress on strategic issues like minority stake buyout STRL.BO Sterlite Industries (India)
of sale of the government's in Balco and Hindustan Zinc have been an overhang on the
residual 49% stake in Bharat stock price, any positive development could act as a catalyst
Aluminium Company (Balco) to and pave the way for potential restructuring in the Vedanta
7-May-2010 Sterlite
FY2010 results Group JSTL.BO JSW Steel
28-May-2010 FY2010 results SAIL.BO Steel Authority of India
3-Jun-2010 FY2010 results NALU.BO National Aluminium Company
25-Jun-2010 FY2010 results Focus would be on Tata Steel Europe's (Corus) earnings TISC.BO Tata Steel
30-Jun-2010 FY2010 results HALC.BO Hindalco Industries
1QFY2011 Commissioning of the first unit of Timely commissioning of the plant could be a potential catalyst STRL.BO Sterlite Industries (India)
its 600 MW commercial power as it will enhance the growth and return profile of the company
plant over the medium term. 25% of its 2400 MW capacity (600 MW)
will be available for sale on merchant basis in the first few
years and we expect Sterlite Energy to contribute 15%/26% to
Sterlite's EBITDA in FY2011E/FY2012E.
1QFY2011 Commissioning of the key As the downstream facilities come on-stream, we expect the JSTL.BO JSW Steel
pritesh.vinay@gs.com
downstream project - 3.5mn Hot share of semis to come down to as low as 2% in FY2011E. This
Pritesh Vinay
Strip Mill would result in margin expansion— for every tonne of semis
91(22)6616-9038
Real Estate Expected Date Event Material Implication / Market Impact Ticker Company
30-Apr-2010 4QFY10 results We look for signs of pick-up in activity in 4Q, particularly DLF.BO DLF
looking out for office absorption momentum. Also to look for
pre-sale receipts in 4Q
14-May-2010 4QFY10 results PARV.BO Parsvnath Developers
14-May-2010 4QFY10 results We look for signs of pick-up in activity in 4Q, particularly UNTE.BO Unitech
looking out for office absorption momentum.
19-May-2010 4QFY10 results SOBH.BO Sobha Developers
vishnu.gopal@gs.com
Vishnu Gopal
91(22)6616-9046
25-May-2010 4QFY10 results We look for updates on status of Airport project, updates on HDIL.BO Housing Development & Infrastructure
TDR sales/prices
4-Jun-2010 4QFY10 results We look for news on Indiabulls Power milestones and status of INRL.BO Indiabulls Real Estate Limited
Mumbai projects
Telecom Expected Date Event Material Implication / Market Impact Ticker Company
sachin.salgaonkar@gs.com
9-Apr-2010 Auction of pan-India 3G and BWA We consider 3G licensing to be a key event which will give the Telecom sector
spectrum spectrum winners a long-term competitive advantage.
28-Apr-2010 4QFY10 results BRTI.BO Bharti Airtel
Sachin Salgaonkar
Utilities Expected Date Event Material Implication / Market Impact Ticker Company
30-Mar-2010 Hearing of Amarkantak Phase LAIN.BO Lanco Infratech
court case
18-Apr-2010 4QFY10 results CHMB.BO Chambal Fertilisers and Chemicals
18-Apr-2010 4QFY10 results UNPO.BO United Phosphorus
19-Apr-2010 4QFY10 results TTPW.BO Tata Power Company
22-Apr-2010 4QFY10 results RPOL.BO Reliance Power
22-Apr-2010 4QFY10 results RLIN.BO Reliance Infrastructure
28-Apr-2010 4QFY10 results TTCH.BO Tata Chemicals
30-Apr-2010 4QFY10 results LAIN.BO Lanco Infratech
Apr-10 RIL-RNRL court case verdict If RNRL were to win, it could potentially add Rs431 to our RPOL.BO Reliance Power
valuation for R-Infra; an adverse decision could potentially
reduce valuation by Rs205
Apr-10 RIL-RNRL court case verdict If RNRL were to win, it could potentially add Rs90 to our RLIN.BO Reliance Infrastructure
durga.dath@gs.com
Source: Company data, Bombay Stock Exchange, Goldman Sachs Research estimates.
Note: Result dates are tentative based on analsyt estimates.
Goldman Sachs India Coverage - Material Events
April-10 RIL-RNRL court case verdict RELI.BO Reliance Industries Buy* 10% We estimate the court case decision could potentially swing valuation by about Nilesh Banerjee
Rs50/sh either way. If RIL were to win, it would likely re-rate the stock
significantly
April-10 RIL-RNRL court case verdict RPOL.BO Reliance Power Sell -21% If RNRL were to win, it could potentially add Rs431 to our valuation for R-Infra; Durga Dath
an adverse decision could potentially reduce valuation by Rs205
April-10 RIL-RNRL court case verdict RLIN.BO Reliance Infrastructure Buy 38% If RNRL were to win, it could potentially add Rs90 to our valuation for RPWR; Durga Dath
an adverse decision could potentially reduce valuation by Rs41
April-10 Salem - Kumarapalyam and Jalandhar - IVRC.BO IVRCL Infrastructure and Buy* 44% As operations stabilize we expect daily collections of Rs1.5-1.7 mn on each of these two Ishan Sethi
Amritsar projects to start tolling Projects BOT projects.
10-May-2010 Pan-India cement dispatch data Cement sector Pritesh Vinay
12-May-2010 March IP We expect the strength in industrial activity to continue Tushar Poddar
14-May-2010 April WPI inflation We expect headline WPI inflation to remain high, although food prices begin to moderate Tushar Poddar
21-May-2010 GDP release We expect 4Q FY10 GDP to be above 8%, in line with very strong readings on Tushar Poddar
IP, PMI and other co-incident indicators.
May-10 Commissioning of Amarkantak Phase II LAIN.BO Lanco Infratech Buy 13% Durga Dath
May-10 Completion of evaluation of techno- BHEL.BO Bharat Heavy Electricals Sell* -27% In stage - 1, NTPC has received 2 bids for boiler supply and 5 for turbine - Ishan Sethi
commercial bids for NTPC's bulk generator sets. We expect BHEL would not be L-1 on the price bids. Thus, we
equipment order and invitation of price expect BHEL to win only 5 of the 11 units at a price matching the lowest bid.
bids thereafter
May - June 2010 Approval of GVK's real estate development GVKP.BO GVK Power and Infrastructure Neutral 7% We expect the company to provide more clarity on the phases of development, timelines Ishan Sethi
plan for the Mumbai Airport by MMRDA and financial details for the real estate development at the airport once the approval has
been secured
10-Jun-2010 Pan-India cement dispatch data Cement sector Pritesh Vinay
12-Jun-2010 April IP We expect the strength in industrial activity to continue Tushar Poddar
14-Jun-2010 May WPI inflation We expect headline WPI inflation to remain high, although food prices begin to moderate Tushar Poddar
30-Jun-10 JLR pension revaluation TAMO.BO Tata Motors Neutral -11% Sandeep Pandya
30-Jun-10 Nissan Micra (compact car) launch MRTI.BO Maruti Suzuki India Neutral 1% Evidence of increasing competition in Indian compact car market Sandeep Pandya
30-Jun-10 Skoda Fabia (compact car) lower priced MRTI.BO Maruti Suzuki India Neutral 1% Evidence of increasing competition in Indian compact car market Sandeep Pandya
version launch
1QFY2011 Cairn India pipeline CAIL.BO Cairn India Ltd. Buy 17% We believe completion and commissioning of the crude pipeline to Salaya Nilesh Banerjee
along with the completion of trains 2 and 3 of Rajasthan crude oil terminal in
1QFY11E could lead to an increase in production volumes at Mangala to
150Kb/d by end-FY11E. With the commissioning of this pipeline, we believe,
Cairn would be able to initiate sales through the pipeline to private refiners
also in 2HCY2010. Cairn already plans to start sales via pipeline to Indian Oil
Corporation in 1QFY11E.
1QFY2011 Announcement of financial terms of JSTL.BO JSW Steel Buy* 8% In our view, strategic alliance with JFE Holdings could eventually lead to JFE Pritesh Vinay
agreement between JFE and JSW investing capital directly in JSW or in JSW's new 10mn tonne expansion project
in Bengal which would be a positive
1QFY2011 At-risk launch of Levodopa SUN.BO Sun Pharmaceutical Industries Sell -32% 30-month stay on Novartis' Levodopa ends in 1Q FY11; depending upon Sun's risk Balaji Prasad
appetite, there could be a potential at-risk launch, which could be positive for the stock.
1QFY2011 Fondaparinux ANDA approval REDY.BO Dr. Reddy's Laboratories Neutral -6% This is one of 2-3 most important products for DRL for 2010. Approval here would have a Balaji Prasad
positive impact on the stock
1QFY2011 Summary judgment from NY Court on SUN.BO Sun Pharmaceutical Industries Sell -32% If the verdict is favorable for Sun, could eliminate some of the Taro overhang on the Balaji Prasad
litigation with Taro stock.
1QFY2011 Commissioning of the first unit of its 600 STRL.BO Sterlite Industries (India) Buy 14% Timely commissioning of the plant could be a potential catalyst as it will Pritesh Vinay
MW commercial power plant enhance the growth and return profile of the company over the medium term.
25% of its 2400 MW capacity (600 MW) will be available for sale on merchant
basis in the first few years and we expect Sterlite Energy to contribute
15%/26% to Sterlite's EBITDA in FY2011E/FY2012E.
1QFY2011 Court hearing on Tarka GLEN.BO Glenmark Pharmaceuticals Neutral 16% 30-month stay on Tarka ends in May and should come up for hearing; significant positive Balaji Prasad
if Glenmark can launch this product in June 10
1QFY2011 Commissioning of the key downstream JSTL.BO JSW Steel Buy* 8% As the downstream facilities come on-stream, we expect the share of semis to Pritesh Vinay
project - 3.5mn Hot Strip Mill come down to as low as 2% in FY2011E. This would result in margin expansion
— for every tonne of semis converted into hot-rolled steel, there is a positive
delta of US$80 per tonne at the EBITDA level
2Q FY2010 FDA reinspection of Dewas plant and its RANB.BO Ranbaxy Laboratories Sell -38% Positive results could remove the overhang on the company Balaji Prasad
1HFY2011 Policy on Banking license Financials Sector Increased competition for Expand banking services to more areas. Tabassum Inamdar
private banks.
Goldman Sachs India Coverage - Events Calendar
Note: Result dates are tentative based on analsyt estimates.
Impacted stocks / sector Material Implication
April Event Ticker Company Market Impact Analyst Sector
First Week (Apr 5 - Apr 11)
9-Apr-2010 Auction of pan-India 3G and BWA Telecom sector We consider 3G licensing to be a key event which will give the Sachin Salgaonkar Telecom
spectrum spectrum winners a long-term competitive advantage.
10-Apr-2010 Pan-India cement dispatch data Cement sector We expect cement dispatch data to be strong till onset of Pritesh Vinay Cement
monsoon in July - FY11E cement consumption forecast at 11%
yoy
May
First Week (May 1 - May 7)
4-May-2010 4QFY10 results HDFC.BO HDFC Tabassum Financials
5-May-2010 4QFY10 results INBK.BO Indusind Bank Tabassum Financials
7-May-2010 4QFY10 results UNBK.BO Union Bank Tabassum Financials
7-May-2010 FY2010 results JSTL.BO JSW Steel Pritesh Vinay Metals
June
2-Jun-2010 4QFY10 results HPCL.BO Hindustan Petroleum Nilesh Banerjee Oil & Gas
3-Jun-2010 FY2010 results NALU.BO National Aluminium Company Pritesh Vinay Metals
4-Jun-2010 4QFY10 results INRL.BO Indiabulls Real Estate Limited We look for news on Indiabulls Power milestones and status of Vishnu Gopal Real Estate
Mumbai projects
10-Jun-2010 Pan-India cement dispatch data Cement sector Pritesh Vinay Cement
12-Jun-2010 April IP We expect the strength in industrial activity to continue Tushar Poddar Economics
14-Jun-2010 May WPI inflation We expect headline WPI inflation to remain high, although food Tushar Poddar Economics
prices begin to moderate
15-Jun-2010 4QFY10 results GAIL.BO Gas Authority of India Nilesh Banerjee Oil & Gas
24-Jun-2010 4QFY10 results ONGC.BO Oil & Natural Gas Corp. Nilesh Banerjee Oil & Gas
25-Jun-2010 FY2010 results TISC.BO Tata Steel Focus would be on Tata Steel Europe's (Corus) earnings Pritesh Vinay Metals
27-Jun-2010 FY2010 results ICMN.BO India Cement Pritesh Vinay Cement
30-Jun-2010 4QFY10 results APLH.BO Apollo Hospitals Balaji Prasad Healthcare
30-Jun-2010 4QFY10 results REDY.BO Dr. Reddy's Laboratories Balaji Prasad Healthcare
30-Jun-2010 4QFY10 results FOHE.BO Fortis Healthcare Balaji Prasad Healthcare
30-Jun-2010 4QFY10 results GLEN.BO Glenmark Pharmaceuticals Balaji Prasad Healthcare
30-Jun-2010 4QFY10 results LUPN.BO Lupin Balaji Prasad Healthcare
30-Jun-2010 4QFY10 results SUN.BO Sun Pharmaceutical Industries Balaji Prasad Healthcare
30-Jun-2010 Skoda Fabia (compact car) lower priced MRTI.BO Maruti Suzuki India Evidence of increasing competition in Indian compact car Sandeep Pandya Autos
version launch market
30-Jun-2010 Nissan Micra (compact car) launch MRTI.BO Maruti Suzuki India Evidence of increasing competition in Indian compact car Sandeep Pandya Autos
30-Jun-2010 JLR pension revaluation TAMO.BO Tata Motors Sandeep Pandya Autos
30-Jun-2010 FY2010 results HALC.BO Hindalco Industries Pritesh Vinay Metals
30-Jun-2010 4QFY10 results GSPT.BO Gujarat State Petronet Nilesh Banerjee Oil & Gas
30-Jun-2010 4QFY10 results OILI.BO Oil India Nilesh Banerjee Oil & Gas
Goldman Sachs India Coverage - Events Calendar
Note: Result dates are tentative based on analsyt estimates.
Impacted stocks / sector Material Implication
April Event Ticker Company Market Impact Analyst Sector
1QFY2011 Cairn India pipeline CAIL.BO Cairn India Ltd. We believe completion and commissioning of the crude Nilesh Banerjee Oil & Gas
pipeline to Salaya along with the completion of trains 2 and 3
of Rajasthan crude oil terminal in 1QFY11E could lead to an
increase in production volumes at Mangala to 150Kb/d by end-
FY11E. With the commissioning of this pipeline, we believe,
Cairn would be able to initiate sales through the pipeline to
private refiners also in 2HCY2010. Cairn already plans to start
sales via pipeline to Indian Oil Corporation in 1QFY11E.
1QFY2011 Fondaparinux ANDA approval REDY.BO Dr. Reddy's Laboratories This is one of 2-3 most imp products for DRL for 2010. Balaji Prasad Healthcare
Approval here would have a positive impact on the stock
1QFY2011 Summary judgment from NY Court on SUN.BO Sun Pharmaceutical Industries If the verdict is favorable for Sun, could eliminate some of the Balaji Prasad Healthcare
litigation with Taro Taro overhang on the stock.
1QFY2011 IPO of Glenmark Generics Ltd - its GLEN.BO Glenmark Pharmaceuticals Clarity on future generics business for Glenmark Balaji Prasad Healthcare
generic business
1QFY2011 Court hearing on Tarka GLEN.BO Glenmark Pharmaceuticals The 30-month stay on Tarka ends in May and should come up Balaji Prasad Healthcare
for hearing; significant positive if Glenmark can launch this
product in June 10
1QFY2011 At-risk launch of Levodopa SUN.BO Sun Pharmaceutical Industries 30-month stay on Novartis' Levodopa ends in 1Q FY11; Balaji Prasad Healthcare
depending upon Sun's risk appetite, there could be a potential
at-risk launch, which could be positive for the stock.
1QFY2011 Listing of Samruddhi Cement (Grasim's GRAS.BO, ULTC.BO Grasim/Ultratech Timely listing of Samruddhi Cement would ensure that the Pritesh Vinay Cement
cement subsidiary) entire consolidation process would be completed by
2QFY2011; implying potential rerating for Ultratech Cements.
Post consolidation,Ultratech Cements would emerge as India’s
largest cement company with a total capacity of 49 mtpa
representing 20% of all-India capacity.
1QFY2011 Commissioning of the first unit of its 600 STRL.BO Sterlite Industries (India) Timely commissioning of the plant could be a potential Pritesh Vinay Metals
MW commercial power plant catalyst as it will enhance the growth and return profile of the
company over the medium term. 25% of its 2400 MW capacity
(600 MW) will be available for sale on merchant basis in the
first few years and we expect Sterlite Energy to contribute
15%/26% to Sterlite's EBITDA in FY2011E/FY2012E.
1QFY2011 Commissioning of the key downstream JSTL.BO JSW Steel As the downstream facilities come on-stream, we expect the Pritesh Vinay Metals
project - 3.5mn Hot Strip Mill share of semis to come down to as low as 2% in FY2011E. This
would result in margin expansion— for every tonne of semis
converted into hot-rolled steel, there is a positive delta of
US$80 per tonne at the EBITDA level
1QFY2011 Announcement of financial terms of JSTL.BO JSW Steel In our view, strategic alliance with JFE Holdings could Pritesh Vinay Metals
agreement between JFE and JSW eventually lead to JFE investing capital directly in JSW or in
JSW's new 10mn tonne expansion project in Bengal which
would be a positive
1QFY2011 Approval of GVK's real estate GVKP.BO GVK Power and Infrastructure We expect the company to provide more clarity on the phases Ishan Sethi Infrastructure
development plan for the Mumbai of development, timelines and financial details for the real
Airport by MMRDA estate development at the airport once the approval has been
2Q FY2010 FDA reinspection of Dewas plant and its RANB.BO Ranbaxy Laboratories secured results could remove the overhang on the company
Positive Balaji Prasad Healthcare
results
1HFY2011 Policy on Banking license Financials Sector Increased competition for private Expand banking services to more areas. Tabassum Financials
banks. Inamdar
Goldman Sachs India Coverage - Earnings Calendar (4QFY2010 / 1QCY2010)
Note: Result dates are tentative based on analsyt estimates.
Material Implication
April Ticker Company Market Impact Analyst Sector Event
First Week (Apr 5 - Apr 11)
May
First Week (May 1 - May 7) 4 companies
4-May-2010 HDFC.BO HDFC Tabassum Inamdar Financials 4QFY10 results
5-May-2010 INBK.BO Indusind Bank Tabassum Inamdar Financials 4QFY10 results
7-May-2010 UNBK.BO Union Bank Tabassum Inamdar Financials 4QFY10 results
7-May-2010 JSTL.BO JSW Steel Pritesh Vinay Metals FY2010 results
June 16 companies
2-Jun-2010 HPCL.BO Hindustan Petroleum Nilesh Banerjee Oil & Gas 4QFY10 results
3-Jun-2010 NALU.BO National Aluminium Company Pritesh Vinay Metals FY2010 results
4-Jun-2010 INRL.BO Indiabulls Real Estate Limited We look for news on Indiabulls Power Vishnu Gopal Real Estate 4QFY10 results
milestones and status of Mumbai
15-Jun-2010 GAIL.BO Gas Authority of India projects Nilesh Banerjee Oil & Gas 4QFY10 results
24-Jun-2010 ONGC.BO Oil & Natural Gas Corp. Nilesh Banerjee Oil & Gas 4QFY10 results
25-Jun-2010 TISC.BO Tata Steel Focus would be on Tata Steel Europe's Pritesh Vinay Metals FY2010 results
(Corus) earnings
27-Jun-2010 ICMN.BO India Cement Pritesh Vinay Cement FY2010 results
30-Jun-2010 APLH.BO Apollo Hospitals Balaji Prasad Healthcare 4QFY10 results
30-Jun-2010 REDY.BO Dr. Reddy's Laboratories Balaji Prasad Healthcare 4QFY10 results
30-Jun-2010 FOHE.BO Fortis Healthcare Balaji Prasad Healthcare 4QFY10 results
30-Jun-2010 GLEN.BO Glenmark Pharmaceuticals Balaji Prasad Healthcare 4QFY10 results
30-Jun-2010 LUPN.BO Lupin Balaji Prasad Healthcare 4QFY10 results
30-Jun-2010 SUN.BO Sun Pharmaceutical Industries Balaji Prasad Healthcare 4QFY10 results
30-Jun-2010 HALC.BO Hindalco Industries Pritesh Vinay Metals FY2010 results
30-Jun-2010 GSPT.BO Gujarat State Petronet Nilesh Banerjee Oil & Gas 4QFY10 results
30-Jun-2010 OILI.BO Oil India Nilesh Banerjee Oil & Gas 4QFY10 results
Reg AC
I, Vikram Sahu, hereby certify that all of the views expressed in this report accurately reflect our personal views about the subject company or c
Investment Profile
The Goldman Sachs Investment Profile provides investment context for a security by comparing key attributes of that security to its peer group
The precise calculation of each metric may vary depending on the fiscal year, industry and region but the standard approach is as follows:
Growth is a composite of next year's estimate over current year's estimate, e.g. EPS, EBITDA, Revenue. Return is a year one prospective aggre
Quantum
Quantum is Goldman Sachs' proprietary database providing access to detailed financial statement histories, forecasts and ratios. It can be used
Disclosures
Coverage group(s) of stocks by primary analyst(s)
Compendium report: please see disclosures at http://www.gs.com/research/hedge.html. Disclosures applicable to the companies included in thi
Company-specific regulatory disclosures
Compendium report: please see disclosures at http://www.gs.com/research/hedge.html. Disclosures applicable to the companies included in thi
Distribution of ratings/investment banking relationships
Goldman Sachs Investment Research global coverage universe
Rating Distribution Investment Banking Relationships
Buy Hold Sell Buy Hold Sell
Global 31% 53% 16% 53% 47% 40%
As of January 1, 2010, Goldman Sachs Global Investment Research had investment ratings on 2,763 equity securities. Goldman Sachs assigns s
Price target and rating history chart(s)
Compendium report: please see disclosures at http://www.gs.com/research/hedge.html. Disclosures applicable to the companies included in thi
Regulatory disclosures
Disclosures required by United States laws and regulations
See company-specific regulatory disclosures above for any of the following disclosures required as to companies referred to in this report: mana
The following are additional required disclosures: Ownership and material conflicts of interest: Goldman Sachs policy prohibits its analysts, p
Distribution of ratings: See the distribution of ratings disclosure above. Price chart: See the price chart, with changes of ratings and price targ
Additional disclosures required under the laws and regulations of jurisdictions other than the United States
The following disclosures are those required by the jurisdiction indicated, except to the extent already made above pursuant to United States la
European Union: Disclosure information in relation to Article 4 (1) (d) and Article 6 (2) of the European Commission Directive 2003/126/EC is av
Japan: Goldman Sachs Japan Co., Ltd. is a Financial Instrument Dealer under the Financial Instrument and Exchange Law, registered with the K
Ratings, coverage groups and views and related definitions
Buy (B), Neutral (N), Sell (S) -Analysts recommend stocks as Buys or Sells for inclusion on various regional Investment Lists. Being assigned a
Return potential represents the price differential between the current share price and the price target expected during the time horizon associ
Coverage groups and views: A list of all stocks in each coverage group is available by primary analyst, stock and coverage group at http://www
Not Rated (NR). The investment rating and target price have been removed pursuant to Goldman Sachs policy when Goldman Sachs is acting
Global product; distributing entities
The Global Investment Research Division of Goldman Sachs produces and distributes research products for clients of Goldman Sachs, and pursu
European Union: Goldman Sachs International, authorized and regulated by the Financial Services Authority, has approved this research in con
General disclosures
This research is for our clients only. Other than disclosures relating to Goldman Sachs, this research is based on current public information that
Goldman Sachs conducts a global full-service, integrated investment banking, investment management, and brokerage business. We have inve
Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients and our pr
We and our affiliates, officers, directors, and employees, excluding equity and credit analysts, will from time to time have long or short position
This research is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would
Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all inv
All research reports are disseminated and available to all clients simultaneously through electronic publication to our internal client websites. N
Disclosure information is also available at http://www.gs.com/research/hedge.html or from Research Compliance, One New York Plaza, New Yor
Copyright 2010 The Goldman Sachs Group, Inc.
No part of this material may be (i) copied, photocopied or duplicated in any form by any means or (ii) redistributed without the
al views about the subject company or companies and its or their securities. We also certify that no part of our compensation was, is or will be, directly or indir
butes of that security to its peer group and market. The four key attributes depicted are: growth, returns, multiple and volatility. Growth, returns and multiple
e standard approach is as follows:
Return is a year one prospective aggregate of various return on capital measures, e.g. CROCI, ROACE, and ROE. Multiple is a composite of one-year forward v
ies, forecasts and ratios. It can be used for in-depth analysis of a single company, or to make comparisons between companies in different sectors and market
icable to the companies included in this compendium can be found in the latest relevant published research.
icable to the companies included in this compendium can be found in the latest relevant published research.
ity securities. Goldman Sachs assigns stocks as Buys and Sells on various regional Investment Lists; stocks not so assigned are deemed Neutral. Such assignm
icable to the companies included in this compendium can be found in the latest relevant published research.
mpanies referred to in this report: manager or co-manager in a pending transaction; 1% or other ownership; compensation for certain services; types of client
an Sachs policy prohibits its analysts, professionals reporting to analysts and members of their households from owning securities of any company in the analy
, with changes of ratings and price targets in prior periods, above, or, if electronic format or if with respect to multiple companies which are the subject of this
other than the United States
ade above pursuant to United States laws and regulations. Australia: This research, and any access to it, is intended only for "wholesale clients" within the m
Commission Directive 2003/126/EC is available at http://www.gs.com/client_services/global_investment_research/europeanpolicy.html which states the Europea
d Exchange Law, registered with the Kanto Financial Bureau (Registration No. 69), and is a member of Japan Securities Dealers Association (JSDA) and Financi
nal Investment Lists. Being assigned a Buy or Sell on an Investment List is determined by a stock's return potential relative to its coverage group as described
xpected during the time horizon associated with the price target. Price targets are required for all covered stocks. The return potential, price target and assoc
stock and coverage group at http://www.gs.com/research/hedge.html. The analyst assigns one of the following coverage views which represents the analyst's
policy when Goldman Sachs is acting in an advisory capacity in a merger or strategic transaction involving this company and in certain other circumstances.
for clients of Goldman Sachs, and pursuant to certain contractual arrangements, on a global basis. Analysts based in Goldman Sachs offices around the world
ority, has approved this research in connection with its distribution in the European Union and United Kingdom; Goldman Sachs & Co. oHG, regulated by the B
ased on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. We see
and brokerage business. We have investment banking and other business relationships with a substantial percentage of the companies covered by our Globa
ding strategies to our clients and our proprietary trading desks that reflect opinions that are contrary to the opinions expressed in this research. Our asset man
ime to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives, if any, referred to in this research.
here such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, f
ntial risk and are not suitable for all investors. Investors should review current options disclosure documents which are available from Goldman Sachs sales re
cation to our internal client websites. Not all research content is redistributed to our clients or available to third-party aggregators, nor is Goldman Sachs resp
mpliance, One New York Plaza, New York, NY 10004.
ns or (ii) redistributed without the prior written consent of The Goldman Sachs Group, Inc.
ation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
volatility. Growth, returns and multiple are indexed based on composites of several methodologies to determine the stocks percentile ranking within the regio
le is a composite of one-year forward valuation ratios, e.g. P/E, dividend yield, EV/FCF, EV/EBITDA, EV/DACF, Price/Book. Volatility is measured as trailing twel
ned are deemed Neutral. Such assignments equate to Buy, Hold and Sell for the purposes of the above disclosure required by NASD/NYSE rules. See 'Ratings,
ion for certain services; types of client relationships; managed/co-managed public offerings in prior periods; directorships; for equity securities, market making
securities of any company in the analyst's area of coverage. Analyst compensation: Analysts are paid in part based on the profitability of Goldman Sachs, wh
companies which are the subject of this report, on the Goldman Sachs website at http://www.gs.com/research/hedge.html.
nly for "wholesale clients" within the meaning of the Australian Corporations Act. Canada: Goldman Sachs & Co. has approved of, and agreed to take responsi
anpolicy.html which states the European Policy for Managing Conflicts of Interest in Connection with Investment Research.
Dealers Association (JSDA) and Financial Futures Association of Japan (FFAJ). Sales and purchase of equities are subject to commission pre-determined with cli
tive to its coverage group as described below. Any stock not assigned as a Buy or a Sell on an Investment List is deemed Neutral. Each regional Investment Re
return potential, price target and associated time horizon are stated in each report adding or reiterating an Investment List membership.
e views which represents the analyst's investment outlook on the coverage group relative to the group's historical fundamentals and/or valuation. Attractive (
ny and in certain other circumstances. Rating Suspended (RS). Goldman Sachs Research has suspended the investment rating and price target for this stock,
oldman Sachs offices around the world produce equity research on industries and companies, and research on macroeconomics, currencies, commodities and
n Sachs & Co. oHG, regulated by the Bundesanstalt für Finanzdienstleistungsaufsicht, may also distribute research in Germany.
hould not be relied on as such. We seek to update our research as appropriate, but various regulations may prevent us from doing so. Other than certain indu
of the companies covered by our Global Investment Research Division. Goldman Sachs & Co., the United States broker dealer, is a member of SIPC (http://www
pressed in this research. Our asset management area, our proprietary trading desks and investing businesses may make investment decisions that are incons
red to in this research.
t the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this
available from Goldman Sachs sales representatives or at http://www.theocc.com/publications/risks/riskchap1.jsp. Transactions cost may be significant in opti
ggregators, nor is Goldman Sachs responsible for the redistribution of our research by third party aggregators. For all research available on a particular stock,
ocks percentile ranking within the region's coverage universe.
red by NASD/NYSE rules. See 'Ratings, Coverage groups and views and related definitions' below.
ps; for equity securities, market making and/or specialist role. Goldman Sachs usually makes a market in fixed income securities of issuers discussed in this re
n the profitability of Goldman Sachs, which includes investment banking revenues. Analyst as officer or director: Goldman Sachs policy prohibits its analysts,
proved of, and agreed to take responsibility for, this research in Canada if and to the extent it relates to equity securities of Canadian issuers. Analysts may co
to commission pre-determined with clients plus consumption tax. See company-specific disclosures as to any applicable disclosures required by Japanese sto
ed Neutral. Each regional Investment Review Committee manages various regional Investment Lists to a global guideline of 25%-35% of stocks as Buy and 10%
List membership.
amentals and/or valuation. Attractive (A). The investment outlook over the following 12 months is favorable relative to the coverage group's historical fundam
nt rating and price target for this stock, because there is not a sufficient fundamental basis for determining an investment rating or target. The previous invest
onomics, currencies, commodities and portfolio strategy. This research is disseminated in Australia by Goldman Sachs JBWere Pty Ltd (ABN 21 006 797 897) o
from doing so. Other than certain industry reports published on a periodic basis, the large majority of reports are published at irregular intervals as appropria
dealer, is a member of SIPC (http://www.sipc.org).
ke investment decisions that are inconsistent with the recommendations or views expressed in this research.
r any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advic
sactions cost may be significant in option strategies calling for multiple purchase and sales of options such as spreads. Supporting documentation will be supp
esearch available on a particular stock, please contact your sales representative or go to http://360.gs.com.
securities of issuers discussed in this report and usually deals as a principal in these securities.
man Sachs policy prohibits its analysts, persons reporting to analysts or members of their households from serving as an officer, director, advisory board mem
s of Canadian issuers. Analysts may conduct site visits but are prohibited from accepting payment or reimbursement by the company of travel expenses for s
e disclosures required by Japanese stock exchanges, the Japanese Securities Dealers Association or the Japanese Securities Finance Company.
e of 25%-35% of stocks as Buy and 10%-15% of stocks as Sell; however, the distribution of Buys and Sells in any particular coverage group may vary as determ
the coverage group's historical fundamentals and/or valuation. Neutral (N). The investment outlook over the following 12 months is neutral relative to the cov
ent rating or target. The previous investment rating and price target, if any, are no longer in effect for this stock and should not be relied upon. Coverage Susp
BWere Pty Ltd (ABN 21 006 797 897) on behalf of Goldman Sachs; in Canada by Goldman Sachs & Co. regarding Canadian equities and by Goldman Sachs & C
professional advice, including tax advice. The price and value of investments referred to in this research and the income from them may fluctuate. Past perform
Supporting documentation will be supplied upon request.
n officer, director, advisory board member or employee of any company in the analyst's area of coverage. Non-U.S. Analysts: Non-U.S. analysts may not be a
y the company of travel expenses for such visits. Hong Kong: Further information on the securities of covered companies referred to in this research may be o
ular coverage group may vary as determined by the regional Investment Review Committee. Regional Conviction Buy and Sell lists represent investment recom
12 months is neutral relative to the coverage group's historical fundamentals and/or valuation. Cautious (C). The investment outlook over the following 12 mo
ould not be relied upon. Coverage Suspended (CS). Goldman Sachs has suspended coverage of this company. Not Covered (NC). Goldman Sachs does not co
ian equities and by Goldman Sachs & Co. (all other research); in Hong Kong by Goldman Sachs (Asia) L.L.C.; in India by Goldman Sachs (India) Securities Priva
e from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur.
alysts: Non-U.S. analysts may not be associated persons of Goldman Sachs & Co. and therefore may not be subject to NASD Rule 2711/NYSE Rules 472 restric
es referred to in this research may be obtained on request from Goldman Sachs (Asia) L.L.C. India: Further information on the subject company or companies
nd Sell lists represent investment recommendations focused on either the size of the potential return or the likelihood of the realization of the return.
tment outlook over the following 12 months is unfavorable relative to the coverage group's historical fundamentals and/or valuation.
ered (NC). Goldman Sachs does not cover this company. Not Available or Not Applicable (NA). The information is not available for display or is not applicable
Goldman Sachs (India) Securities Private Ltd.; in Japan by Goldman Sachs Japan Co., Ltd.; in the Republic of Korea by Goldman Sachs (Asia) L.L.C., Seoul Bran
and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain inv
NASD Rule 2711/NYSE Rules 472 restrictions on communications with subject company, public appearances and trading securities held by the analysts.
on the subject company or companies referred to in this research may be obtained from Goldman Sachs (India) Securities Private Limited; Japan: See below. K
available for display or is not applicable. Not Meaningful (NM). The information is not meaningful and is therefore excluded.
Goldman Sachs (Asia) L.L.C., Seoul Branch; in New Zealand by Goldman Sachs JBWere (NZ) Limited on behalf of Goldman Sachs; in Russia by OOO Goldman Sa
ies Private Limited; Japan: See below. Korea: Further information on the subject company or companies referred to in this research may be obtained from Gol
n Sachs; in Russia by OOO Goldman Sachs; in Singapore by Goldman Sachs (Singapore) Pte. (Company Number: 198602165W); and in the United States of Am
his research may be obtained from Goldman Sachs (Asia) L.L.C., Seoul Branch. Russia: Research reports distributed in the Russian Federation are not advertis
2165W); and in the United States of America by Goldman Sachs & Co. Goldman Sachs International has approved this research in connection with its distribut
the Russian Federation are not advertising as defined in the Russian legislation, but are information and analysis not having product promotion as their main p
esearch in connection with its distribution in the United Kingdom and European Union.
ving product promotion as their main purpose and do not provide appraisal within the meaning of the Russian legislation on appraisal activity. Singapore: Fur
on on appraisal activity. Singapore: Further information on the covered companies referred to in this research may be obtained from Goldman Sachs (Singapo
obtained from Goldman Sachs (Singapore) Pte. (Company Number: 198602165W). Taiwan: This material is for reference only and must not be reprinted withou
e only and must not be reprinted without permission. Investors should carefully consider their own investment risk. Investment results are the responsibility of
stment results are the responsibility of the individual investor. United Kingdom: Persons who would be categorized as retail clients in the United Kingdom, as
retail clients in the United Kingdom, as such term is defined in the rules of the Financial Services Authority, should read this research in conjunction with prior
this research in conjunction with prior Goldman Sachs research on the covered companies referred to herein and should refer to the risk warnings that have b
d refer to the risk warnings that have been sent to them by Goldman Sachs International. A copy of these risks warnings, and a glossary of certain financial te
s, and a glossary of certain financial terms used in this report, are available from Goldman Sachs International on request.
Goldman Sachs India Coverage - Events Calendar